



LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
CORE PHARMACY & THERAPEUTICS COMMITTEE

December 1st, 2017

TO: DHS Core P&T Committee
MHLA Clinics

FROM: Jeffrey Guterman, M.D.
Shane D'Souza, Pharm.D.
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: December 2017 DHS Core Formulary Decisions

MY HEALTH LA FORMULARY

Formulary Changes

Drug Product	Comments
Insulin Detemir 100 units/mL (Levemir® brand)	Quantity Limit change: Maximum of 6 vials within any 30-day period
Insulin Lispro 100 units/mL (Humalog® brand)	Quantity Limit change: Maximum of 6 vials within any 30-day period
Insulin NPH 100 units/mL (Novolin® brand)	Quantity Limit change: Maximum of 6 vials within any 30-day period
Insulin NPH/Regular 70/30 100 units/mL (Novolin® brand)	Quantity Limit change: Maximum of 6 vials within any 30-day period
Insulin Regular 100 units/mL (Novolin® brand)	Quantity Limit change: Maximum of 6 vials within any 30-day period
Digoxin 0.125mg, 0.25mg oral tablet (Lanoxin® brand)	340B pharmacy dispensing only
Methotrexate 2.5mg oral tablet	340B pharmacy dispensing only

Drug Deletion

Drug Product	Comments
Albuterol 2mg, 4mg oral tablet	Alternatives available on the MHLA Formulary (i.e., albuterol oral syrup for pediatrics and albuterol inhalers for adults)

This document contains confidential information intended for Los Angeles County Health Professionals and employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.